

# Victoria P Werth

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8631746/victoria-p-werth-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

304  
papers

12,888  
citations

53  
h-index

106  
g-index

383  
ext. papers

16,231  
ext. citations

4  
avg, IF

6.52  
L-index

#	Paper	IF	Citations
304	Cutaneous Lupus <b>2022</b> , 25-52		
303	Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of Lenabasum.. <i>Arthritis Research and Therapy</i> , <b>2022</b> , 24, 12	5.7	0
302	Rho Kinase regulates neutrophil NET formation that is involved in UVB-induced skin inflammation.. <i>Theranostics</i> , <b>2022</b> , 12, 2133-2149	12.1	2
301	Letter to the Editor Reply Regarding ACR White Paper on Antimalarials and Cardiac Toxicity: Suggested Amendments to Future Directions.. <i>Arthritis and Rheumatology</i> , <b>2022</b> ,	9.5	
300	Mycophenolate Mofetil and Methotrexate Efficacy in Dermatomyositis.. <i>British Journal of Dermatology</i> , <b>2022</b> ,	4	
299	Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials.. <i>Lupus</i> , <b>2022</b> , 9612033221084093	2.6	0
298	SCLEROTIC SKIN DISEASE DEVELOPMENT FOLLOWING COVID-19 VACCINATION.. <i>JAAD Case Reports</i> , <b>2022</b> ,	1.4	2
297	How do experts treat patients with bullous pemphigoid around the world? An international survey.. <i>JID Innovations</i> , <b>2022</b> , 100129		
296	Defining anti-synthetase syndrome: a systematic literature review.. <i>Clinical and Experimental Rheumatology</i> , <b>2022</b> , 40, 309-319	2.2	0
295	Importance of collaboration of dermatology and rheumatology to advance the field for lupus and dermatomyositis.. <i>International Journal of Women's Dermatology</i> , <b>2021</b> , 7, 583-587	2	0
294	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	7
293	American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 2151-2160	9.5	2
292	The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. <i>Annals of Translational Medicine</i> , <b>2021</b> , 9, 431	3.2	1
291	Environmental triggers of dermatomyositis: a narrative review. <i>Annals of Translational Medicine</i> , <b>2021</b> , 9, 434	3.2	6
290	American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 908-911	9.5	10
289	Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	11
288	Immunological and clinical heterogeneity in cutaneous lupus erythematosus. <i>British Journal of Dermatology</i> , <b>2021</b> , 185, 480-481	4	1

287	Clinical characteristics of itch in cutaneous lupus erythematosus: A prospective, multicenter, multinational, cross-sectional study. <i>Lupus</i> , <b>2021</b> , 30, 1385-1393	2.6	0
286	Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus. <i>Journal of Investigative Dermatology</i> , <b>2021</b> , 141, 2858-2865.e4	4.3	5
285	Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 2295-2305	59.2	14
284	Drug-induced subacute cutaneous lupus erythematosus in previously diagnosed systemic lupus erythematosus patients: A case series. <i>JAAD Case Reports</i> , <b>2021</b> , 12, 18-21	1.4	1
283	Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study. <i>British Journal of Dermatology</i> , <b>2021</b> , 185, 745-755	4	13
282	Individual patientsPrisk factors impact guidelines for prophylactic agents used in pemphigus patients treated with rituximab. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, e47-e48	4.5	
281	The incidence of bullous pemphigoid continues to increase in England. <i>British Journal of Dermatology</i> , <b>2021</b> , 184, 5-6	4	1
280	The effects of immunostimulatory herbal supplements on autoimmune skin diseases. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1051-1058	4.5	4
279	Patient-oriented outcomes for atopic dermatitis. <i>British Journal of Dermatology</i> , <b>2021</b> , 184, 794-795	4	
278	Response of dermatomyositis to the antimalarial quinacrine: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1157-1160	4.5	
277	Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1562-1567	4.5	2
276	Establishing cut-off values for mild, moderate and severe disease in patients with pemphigus using the Pemphigus Disease Area Index. <i>British Journal of Dermatology</i> , <b>2021</b> , 184, 975-977	4	1
275	Wong-Type Dermatomyositis in an African American Patient. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 630	9.5	1
274	Identifying the required degree of disease clearance to improve quality of life in pemphigus vulgaris. <i>British Journal of Dermatology</i> , <b>2021</b> , 184, 573-575	4	1
273	Accuracy of commercial panels to evaluate myositis autoantibodies: A single-institution perspective. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 572-574	4.5	2
272	Increased MxA protein expression and dendritic cells in spongiotic dermatitis differentiates dermatomyositis from eczema in a single-center case-control study. <i>Journal of Cutaneous Pathology</i> , <b>2021</b> , 48, 364-373	1.7	2
271	Response to: Correspondence on EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups by Irfan. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	1
270	Plasma-derived DNA containing-extracellular vesicles induce STING-mediated proinflammatory responses in dermatomyositis. <i>Theranostics</i> , <b>2021</b> , 11, 7144-7158	12.1	3

269	The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	1
268	A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. <i>Rheumatology</i> , <b>2021</b> , 60, 2615-2628	3.9	12
267	Myeloid Dendritic Cells Are Major Producers of IFN- $\gamma$ in Dermatomyositis and May Contribute to Hydroxychloroquine Refractoriness. <i>Journal of Investigative Dermatology</i> , <b>2021</b> , 141, 1906-1914.e2	4.3	3
266	Highly Multiplexed Mass Cytometry Identifies the Immunophenotype in the Skin of Dermatomyositis. <i>Journal of Investigative Dermatology</i> , <b>2021</b> , 141, 2151-2160	4.3	4
265	Filgotinib or Lanraplenib in Moderate to Severe Cutaneous Lupus Erythematosus: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study. <i>Rheumatology</i> , <b>2021</b> ,	3.9	1
264	Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis.. <i>International Journal of Women's Dermatology</i> , <b>2021</b> , 7, 560-575	2	1
263	A Multidisciplinary Collaborative Approach to Retinal Toxic Effects Screening for Dermatology Patients Taking Antimalarials. <i>JAMA Dermatology</i> , <b>2021</b> , 157, 1112-1113	5.1	1
262	Dermatomyositis associated with hyponatremia and anasarca. <i>JAAD Case Reports</i> , <b>2021</b> , 16, 86-89	1.4	1
261	Erythromelalgia associated with dermatomyositis: A case series. <i>JAAD Case Reports</i> , <b>2021</b> , 16, 37-40	1.4	1
260	Candidate drug replacements for quinacrine in cutaneous lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2020</b> , 7,	4.6	1
259	The early local and systemic Type I interferon responses to ultraviolet B light exposure are cGAS dependent. <i>Scientific Reports</i> , <b>2020</b> , 10, 7908	4.9	24
258	Creation and Validation of Classification Criteria for Discoid Lupus Erythematosus. <i>JAMA Dermatology</i> , <b>2020</b> , 156, 901-906	5.1	6
257	Evaluating the effect of prior authorizations in patients with complex dermatologic conditions. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 1674-1680	4.5	2
256	Malignancy in dermatomyositis: A retrospective study of 201 patients seen at the University of Pennsylvania. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 117-122	4.5	8
255	The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 458-462	5.3	2
254	Photosensitivity in Lupus Erythematosus and Dermatomyositis. <i>Current Dermatology Reports</i> , <b>2020</b> , 9, 93-99	1.5	2
253	Nuclear envelope rupture and NET formation is driven by PKC $\epsilon$ -mediated lamin B disassembly. <i>EMBO Reports</i> , <b>2020</b> , 21, e48779	6.5	17
252	Custom dental trays with topical corticosteroids for management of gingival lesions of mucous membrane pemphigoid. <i>International Journal of Dermatology</i> , <b>2020</b> , 59, e211-e213	1.7	2

251	Cutaneous lupus erythematosus induced by drugs - novel insights. <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 35-42	3.8	13
250	Response letter to Rchronic cutaneous lupus erythematosus induced by 5-fluorouracilP <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 919-920	3.8	
249	Systemic sclerosis: Update for oral health care providers. <i>Special Care in Dentistry</i> , <b>2020</b> , 40, 418-430	1.7	2
248	Effect of TNF $\beta$ blockade on UVB-induced inflammatory cell migration and collagen loss in mice. <i>Journal of Photochemistry and Photobiology B: Biology</i> , <b>2020</b> , 213, 112072	6.7	6
247	Expert Perspective: An Evidence-Based Approach to Refractory Cutaneous Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1777-1785	9.5	1
246	An Update on the Pathogenesis of Cutaneous Lupus Erythematosus and Its Role in Clinical Practice. <i>Current Rheumatology Reports</i> , <b>2020</b> , 22, 69	4.9	5
245	Diagnosis and management of pemphigus: Recommendations of an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 575-585.e1	4.5	127
244	Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 949-954	4	6
243	Blood plasma versus serum: which is right for sampling circulating membrane microvesicles in human subjects?. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, e73	2.4	8
242	Developing classification criteria for skin-predominant dermatomyositis: the Delphi process. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 410-417	4	16
241	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. <i>Neuromuscular Disorders</i> , <b>2020</b> , 30, 70-92	2.9	53
240	Recent Advances in Pharmacological Treatments of Adult Dermatomyositis. <i>Current Rheumatology Reports</i> , <b>2019</b> , 21, 53	4.9	4
239	Launching lollipops? Perforating osteoma cutis in nephrogenic systemic fibrosis. <i>Journal of Cutaneous Pathology</i> , <b>2019</b> , 46, 467-470	1.7	2
238	A review of cutaneous lupus erythematosus: improving outcomes with a multidisciplinary approach. <i>Journal of Multidisciplinary Healthcare</i> , <b>2019</b> , 12, 419-428	2.8	11
237	Understanding cutaneous lupus erythematosus: a step forward. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 1292-1293	4	1
236	Utilization patterns and performance of commercial myositis autoantibody panels in routine clinical practice. <i>British Journal of Dermatology</i> , <b>2019</b> , 181, 1090-1092	4	5
235	Examining cutaneous disease activity as an outcome measure for clinical trials in dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 1793-1794	4.5	5
234	Geospatial Correlation of Amyopathic Dermatomyositis With Fixed Sources of Airborne Pollution: A Retrospective Cohort Study. <i>Frontiers in Medicine</i> , <b>2019</b> , 6, 85	4.9	2

233	Cutaneous Lupus Erythematosus Patients With a Negative Antinuclear Antibody Meeting the American College of Rheumatology and/or Systemic Lupus International Collaborating Clinics Criteria for Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 1404-1409	4.7	9
232	Effect of Hydroxychloroquine and Anti-BDCA2 mAb Treatment on pDC IFN $\gamma$ Production From Patients Affected With Cutaneous Lupus Erythematosus. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 275	8.4	19
231	Evaluating results of an interferon- $\gamma$ release assay in patients with autoimmune disease who are taking hydroxychloroquine. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 1162-1164	4.5	0
230	Evaluating cutaneous lupus disease activity end points and their effects on quality of life as an outcome measure for clinical trials. <i>British Journal of Dermatology</i> , <b>2019</b> , 181, 841-842	4	4
229	Practice-based differences in paediatric discoid lupus erythematosus. <i>British Journal of Dermatology</i> , <b>2019</b> , 181, 805-810	4	7
228	Acute onset/flare of dermatomyositis following ingestion of IsaLean herbal supplement: Clinical and immunostimulatory findings. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 801-804	4.5	6
227	Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among paediatric dermatologists and rheumatologists. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 165-171	4	10
226	Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus. <i>JAMA Dermatology</i> , <b>2019</b> , 155, 1404-1409	5.1	26
225	1004 Increased tissue-resident memory T (TRM) cells and STAT3 expression in cutaneous lupus erythematosus patients refractory to antimalarials. <i>Journal of Investigative Dermatology</i> , <b>2019</b> , 139, S174-3	4.3	2
224	Relative risk of microscopic colitis in dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 81, 1188-1190	4.5	1
223	Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 1359-1371	15.9	110
222	Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus. <i>F1000Research</i> , <b>2019</b> , 8,	3.6	8
221	Cutaneous Outcome Measures of Adult Dermatomyositis <b>2019</b> , 1-7		
220	10 Annual Meeting of the Rheumatologic Dermatology Society. <i>Annals of Translational Medicine</i> , <b>2019</b> , 7, S159	3.2	1
219	Management of autoimmune blistering diseases in pregnancy and the neonate. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , <b>2019</b> , 154, 539-549	0.8	
218	Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2571	8.4	6
217	The diagnosis and classification of amyopathic dermatomyositis: a historical review and assessment of existing criteria. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 1001-1008	4	21
216	Management of Cutaneous Lupus Erythematosus <b>2019</b> , 719-726		

215	Bullous pemphigoid in adolescence. <i>Pediatric Dermatology</i> , <b>2019</b> , 36, 184-188	1.9	6
214	Supplementing Dermatology Physician Resident Education in Vasculitis and Autoimmune Connective Tissue Disease: A Prospective Study of an Online Curriculum. <i>JAMA Dermatology</i> , <b>2019</b> , 155, 381-383	5.1	5
213	Increased Myeloid Dendritic Cells and TNF- $\alpha$ Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus. <i>Journal of Investigative Dermatology</i> , <b>2019</b> , 139, 324-332	4.3	20
212	Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations. <i>Journal of Investigative Dermatology</i> , <b>2019</b> , 139, 270-276	4.3	12
211	Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. <i>Journal of Investigative Dermatology</i> , <b>2019</b> , 139, 31-37	4.3	33
210	Fatigue in systemic lupus erythematosus and other autoimmune skin diseases. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 1468-1472	4	6
209	Itch in dermatomyositis: the role of increased skin interleukin-31. <i>British Journal of Dermatology</i> , <b>2018</b> , 179, 669-678	4	36
208	Lupus community panel proposals for optimising clinical trials: 2018. <i>Lupus Science and Medicine</i> , <b>2018</b> , 5, e000258	4.6	43
207	Systemic sclerosis: Current concepts of skin and systemic manifestations. <i>Clinics in Dermatology</i> , <b>2018</b> , 36, 459-474	3	17
206	Classification of myositis. <i>Nature Reviews Rheumatology</i> , <b>2018</b> , 14, 269-278	8.1	117
205	Treatment of Autoimmune Bullous Disorders in Pregnancy. <i>American Journal of Clinical Dermatology</i> , <b>2018</b> , 19, 391-403	7.1	15
204	Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus. <i>British Journal of Dermatology</i> , <b>2018</b> , 178, 1308-1314	4	10
203	Applicability of EULAR/ACR classification criteria for dermatomyositis to amyopathic disease. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 79, 77-83.e1	4.5	26
202	Dermatomyositis: A diagnostic dilemma. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 79, 371-373	4.3	16
201	Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, 100-106.e1	4.5	30
200	Cutaneous dermatomyositis disease course followed over time using the Cutaneous Dermatomyositis Disease Area and Severity Index. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 79, 464-469.e2	4.5	10
199	Re-examining mechanic hands as a characteristic skin finding in dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, 769-775.e2	4.5	16
198	1081 BIIB059, a monoclonal antibody targeting BDCA2, decreases Type I Interferon-related genes transcriptional activity in subjects with systemic lupus erythematosus (SLE) and active cutaneous LE (CLE). <i>Journal of Investigative Dermatology</i> , <b>2018</b> , 138, S183	4.3	2

197	Disease severity and prophylactic measures in patients with cutaneous lupus erythematosus: results of a worldwide questionnaire-based study. <i>Postepy Dermatologii I Alergologii</i> , <b>2018</b> , 35, 192-198	1.5	3
196	Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional Study. <i>BioMed Research International</i> , <b>2018</b> , 2018, 3491798	3	7
195	Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept. <i>JAAD Case Reports</i> , <b>2018</b> , 4, 698-700	1.4	12
194	Natural history of disease activity and damage in patients with cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 79, 1053-1060.e3	4.5	4
193	FRI0470 A phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis <b>2018</b> ,		2
192	605 Study of safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis. <i>Journal of Investigative Dermatology</i> , <b>2018</b> , 138, S103	4.3	2
191	Alopecias in lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2018</b> , 5, e000291	4.6	23
190	Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2018</b> , 5, e000284	4.6	31
189	Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. <i>Lancet, The</i> , <b>2018</b> , 392, 1330-1339	4.0	161
188	Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference. <i>Frontiers in Medicine</i> , <b>2018</b> , 5, 306	4.9	15
187	Drug-induced dermatomyositis after lacosamide: A case report. <i>JAAD Case Reports</i> , <b>2018</b> , 4, 584-585	1.4	4
186	Pulmonary function tests, interstitial lung disease and lung function decline in outpatients with classic and clinically amyopathic dermatomyositis. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 262-264	4	4
185	Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 231-233	4	13
184	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 554-561	2.4	175
183	Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Infectious complications and vaccination recommendations. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 191-198	4.5	39
182	Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 201-207	4.5	43
181	Brief Report: Pharmacodynamics, Safety, and Clinical Efficacy of AMG 811, a Human Anti-Interferon- $\gamma$ Antibody, in Patients With Discoid Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1028-1034	9.5	50
180	Dermatological evaluation in patients with skin of colour: the effect of erythema on outcome measures in atopic dermatitis. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 853-854	4	4



179	Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists. <i>British Journal of Dermatology</i> , <b>2017</b> , 177, 1086-1092	4	17
178	Development of classification criteria for discoid lupus erythematosus: Results of a Delphi exercise. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 77, 261-267	4.5	34
177	The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 423-430	4	12
176	Prevention and management of glucocorticoid-induced side effects: A comprehensive review: A review of glucocorticoid pharmacology and bone health. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 1-9	4.5	81
175	Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Gastrointestinal and endocrinologic side effects. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 11-16	4.5	45
174	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1955-1964	2.4	393
173	Quinacrine Suppresses Tumor Necrosis Factor- $\alpha$ and IFN- $\gamma$ in Dermatomyositis and Cutaneous Lupus Erythematosus. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , <b>2017</b> , 18, S57-S63	1.1	21
172	SAT0255 A randomized, placebo-controlled, double-blind, ascending-dose, safety study of CC-220 in subjects with systemic lupus erythematosus <b>2017</b> ,		3
171	Effect of long-term treatment with tumour necrosis factor- $\alpha$ inhibitors on single-dose ultraviolet-induced changes in human skin. <i>British Journal of Dermatology</i> , <b>2017</b> , 177, 1762-1764	4	1
170	The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 77, 374-377	4.5	10
169	The systemic management of cutaneous dermatomyositis: Results of a stepwise strategy. <i>International Journal of Women's Dermatology</i> , <b>2017</b> , 3, 189-194	2	23
168	Importance of recognition and improved treatment for antimelanoma differentiation-associated protein 5-associated dermatomyositis. <i>British Journal of Dermatology</i> , <b>2017</b> , 177, 1168-1169	4	1
167	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. <i>RMD Open</i> , <b>2017</b> , 3, e000507	5.9	66
166	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 2271-2282	9.5	210
165	Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor- $\alpha$ and Type I Interferons in Dermatomyositis In Vitro. <i>Journal of Investigative Dermatology</i> , <b>2017</b> , 137, 2445-2447	4.3	22
164	Anifrolumab, an Anti-Interferon- $\gamma$ Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 376-386	9.5	430
163	Biological therapies in the treatment of cutaneous lupus erythematosus. <i>Lupus</i> , <b>2017</b> , 26, 115-118	2.6	24
162	Accidental hydroxychloroquine overdose resulting in neurotoxic vestibulopathy. <i>BMJ Case Reports</i> , <b>2017</b> , 2017,	0.9	10

161	Practice and Educational Gaps in Lupus, Dermatomyositis, and Morphea. <i>Dermatologic Clinics</i> , <b>2016</b> , 34, 243-50	4.2	7
160	Microvesicles in Autoimmune Diseases. <i>Advances in Clinical Chemistry</i> , <b>2016</b> , 77, 125-175	5.8	32
159	Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects. <i>Expert Review of Clinical Immunology</i> , <b>2016</b> , 12, 1109-21	5.1	10
158	The incidence of herpes zoster in cutaneous lupus erythematosus (CLE), dermatomyositis (DM), pemphigus vulgaris (PV), and bullous pemphigoid (BP). <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 75, 42-8	4.5	6
157	Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin Inflammation. <i>Journal of Investigative Dermatology</i> , <b>2016</b> , 136, 1990-2002	4.3	20
156	A cross-sectional study of untreated depression and anxiety in cutaneous lupus erythematosus and dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 74, 377-9	4.5	23
155	Management of rheumatic and autoimmune blistering disease in pregnancy and postpartum. <i>Clinics in Dermatology</i> , <b>2016</b> , 34, 344-52	3	17
154	Treatment of cutaneous lupus erythematosus: current practice variations. <i>Lupus</i> , <b>2016</b> , 25, 964-72	2.6	12
153	Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment. <i>American Journal of Clinical Dermatology</i> , <b>2016</b> , 17, 135-46	7.1	62
152	Using the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC) criteria to determine the diagnosis of systemic lupus erythematosus (SLE) in patients with subacute cutaneous lupus erythematosus (SCLE). <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 74, 862-9	4.5	23
151	Cutaneous Lupus Erythematosus: Current Treatment Options. <i>Current Treatment Options in Rheumatology</i> , <b>2016</b> , 2, 36-48	1.3	4
150	Classifying discoid lupus erythematosus: background, gaps, and difficulties. <i>International Journal of Women's Dermatology</i> , <b>2016</b> , 2, 8-12	2	5
149	Pemphigoid Gestationis <b>2016</b> , 149-162		
148	Translocation of Endogenous Danger Signal HMGB1 From Nucleus to Membrane Microvesicles in Macrophages. <i>Journal of Cellular Physiology</i> , <b>2016</b> , 231, 2319-26	7	37
147	Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 142-9	4	52
146	Sifalimumab, an anti-interferon- $\gamma$ monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1909-1916	2.4	309
145	Developing classification criteria for discoid lupus erythematosus: an update from the World Congress of Dermatology 2015 meeting. <i>International Journal of Women's Dermatology</i> , <b>2016</b> , 2, 44-45	2	4
144	213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015. <i>Neuromuscular Disorders</i> , <b>2016</b> , 26, 523-34	2.9	12

143	Ice-pack Dermatitis: A Diagnostic Pitfall for Dermatopathologists that Mimics Lupus Erythematosus. <i>Journal of Cutaneous Pathology</i> , <b>2016</b> , 43, 1-4	1.7	3
142	Reliability of the autoimmune bullous disease quality of life (ABQOL) questionnaire in the USA. <i>Quality of Life Research</i> , <b>2015</b> , 24, 2257-60	3.7	20
141	The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. <i>Cytokine</i> , <b>2015</b> , 73, 326-344		50
140	Redefining cutaneous lupus erythematosus: a proposed international consensus approach and results of a preliminary questionnaire. <i>Lupus Science and Medicine</i> , <b>2015</b> , 2, e000085	4.6	17
139	Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 952-60	5.1	66
138	Reliability and Validity of Cutaneous Sarcoidosis Outcome Instruments Among Dermatologists, Pulmonologists, and Rheumatologists. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 1317-1322	5.1	14
137	Small vessel vasculitis of the skin. <i>Rheumatic Disease Clinics of North America</i> , <b>2015</b> , 41, 21-32, vii	2.4	46
136	A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. <i>British Journal of Dermatology</i> , <b>2015</b> , 172, 760-8	4	36
135	Decreased secretion of adiponectin through its intracellular accumulation in adipose tissue during tobacco smoke exposure. <i>Nutrition and Metabolism</i> , <b>2015</b> , 12, 15	4.6	14
134	Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life. <i>British Journal of Dermatology</i> , <b>2015</b> , 172, 169-74	4	23
133	Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change. <i>British Journal of Dermatology</i> , <b>2015</b> , 173, 969-74	4	47
132	Cutaneous lupus erythematosus flare following exposure to surgical light during a dental procedure. <i>BMJ Case Reports</i> , <b>2015</b> , 2015,	0.9	1
131	Pathophysiology of cutaneous lupus erythematosus. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 182	5.7	65
130	Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 168-74	4.5	93
129	Dapsone and Autoimmune Bullous Disorders <b>2015</b> , 493-499		
128	Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 70, 583-4	4.5	33
127	A47: Progress Report on the Development of New Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, S70-S71	9.5	12
126	The impact of skin damage due to cutaneous lupus on quality of life. <i>British Journal of Dermatology</i> , <b>2014</b> , 170, 315-21	4	34

125	Challenges in measuring outcomes: size assessment of an individual cutaneous lesion. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 71, 402-4	4.5	
124	Bullous Pemphigoid, Mucous Membrane Pemphigoid and Pemphigus Vulgaris: An Update on Pathobiology. <i>Current Oral Health Reports</i> , <b>2014</b> , 1, 180-189	1.2	1
123	Grading criteria for disease severity by pemphigus disease area index. <i>Journal of Dermatology</i> , <b>2014</b> , 41, 969-73	1.6	32
122	Thalidomide-induced orofacial neuropathy. <i>Journal of Clinical Rheumatology</i> , <b>2014</b> , 20, 399-400	1.1	7
121	Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. <i>JAMA Dermatology</i> , <b>2014</b> , 150, 291-6	5.1	61
120	Characterization of clinical photosensitivity in cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , <b>2013</b> , 69, 205-13	4.5	32
119	Cutaneous lupus erythematosus: diagnosis and treatment. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2013</b> , 27, 391-404	5.3	152
118	Update on Epidemiology and Clinical Assessment Tools of Cutaneous Lupus Erythematosus and Dermatomyositis. <i>Current Dermatology Reports</i> , <b>2013</b> , 2, 48-57	1.5	
117	Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy. <i>Dermatologic Therapy</i> , <b>2013</b> , 26, 354-63	2.2	31
116	Pemphigus. <i>Dental Clinics of North America</i> , <b>2013</b> , 57, 597-610	3.3	39
115	A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus. <i>British Journal of Dermatology</i> , <b>2013</b> , 168, 145-53	4	40
114	Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis. <i>JAMA Dermatology</i> , <b>2013</b> , 149, 550-6	5.1	25
113	Update on pathogenesis and treatment of CLE. <i>Current Opinion in Rheumatology</i> , <b>2013</b> , 25, 584-90	5.3	15
112	Skin Disease in Cutaneous Lupus Erythematosus <b>2013</b> , 319-332		2
111	Quality of life differences between responders and nonresponders in the treatment of cutaneous lupus erythematosus. <i>JAMA Dermatology</i> , <b>2013</b> , 149, 104-6	5.1	23
110	OP0035 Progress Report on the Development of New Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A60.2-A60	2.4	
109	The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 128-34	2.2	30
108	Measurement of disease severity in cutaneous autoimmune diseases. <i>F1000prime Reports</i> , <b>2013</b> , 5, 19		3

107	THU0241 Ethnic but not gender differences in disease manifestations in dermatomyositis patients. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 236.3-236	2.4	
106	Update on management of connective tissue panniculitides. <i>Dermatologic Therapy</i> , <b>2012</b> , 25, 173-82	2.2	24
105	The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. <i>British Journal of Dermatology</i> , <b>2012</b> , 166, 971-5	4	89
104	Dapsone in the management of autoimmune bullous diseases. <i>Immunology and Allergy Clinics of North America</i> , <b>2012</b> , 32, 317-22, vii	3.3	13
103	Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. <i>Archives of Dermatology</i> , <b>2012</b> , 148, 1031-6		86
102	Prevalence of self-report photosensitivity in cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , <b>2012</b> , 66, 220-8	4.5	37
101	Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. <i>Journal of the American Academy of Dermatology</i> , <b>2012</b> , 66, 571-82	4.5	43
100	Quality of life in patients with bullous dermatoses. <i>Clinics in Dermatology</i> , <b>2012</b> , 30, 103-7	3	27
99	Tumor necrosis factor $\alpha$ release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients. <i>Arthritis Research and Therapy</i> , <b>2012</b> , 14, R1	5.7	28
98	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 2677-86		2688
97	Gottron <sup>®</sup> papules exhibit dermal accumulation of CD44 variant 7 (CD44v7) and its binding partner osteopontin: a unique molecular signature. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 1825-32	4.3	16
96	Impact of smoking in cutaneous lupus erythematosus. <i>Archives of Dermatology</i> , <b>2012</b> , 148, 317-22		75
95	Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 1117-24	4.3	32
94	Dapsone in the management of autoimmune bullous diseases. <i>Dermatologic Clinics</i> , <b>2011</b> , 29, 561-4	4.2	19
93	Quality of life in cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 64, 849-58	4.5	103
92	A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 64, 903-8	4.5	100
91	Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 64, 217-28; quiz 229-30	4.5	249
90	Update on morphea: part II. Outcome measures and treatment. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 64, 231-42; quiz 243-4	4.5	122

89	Quality of life in dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 65, 1107-16	4.5	62
88	Rituximab in the treatment of bullous systemic lupus erythematosus. <i>Journal of Clinical Rheumatology</i> , <b>2011</b> , 17, 142-4	1.1	29
87	Squamous cell carcinomas arising in discoid lupus erythematosus scars: unusual occurrence in an African-American and in a sun-protected area. <i>Journal of Clinical Rheumatology</i> , <b>2011</b> , 17, 35-6	1.1	18
86	Animal models of acute photodamage: comparisons of anatomic, cellular and molecular responses in C57BL/6J, SKH1 and Balb/c mice. <i>Photochemistry and Photobiology</i> , <b>2011</b> , 87, 690-8	3.6	26
85	Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. <i>Autoimmunity Reviews</i> , <b>2011</b> , 10, 383-8	13.6	55
84	Treatment of cutaneous lupus. <i>Current Rheumatology Reports</i> , <b>2011</b> , 13, 300-7	4.9	46
83	Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity	4.7	203
82	Dermatomyositis autoantibodies: clinical markers of patients past, present, and future. <i>Archives of Dermatology</i> , <b>2011</b> , 147, 492-4		7
81	Quantitative Muscle T. <i>Arthritis Care and Research</i> , <b>2011</b> , 63 Suppl 11, S118-57		
81	Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. <i>Archives of Dermatology</i> , <b>2011</b> , 147, 203-8		101
80	Identification and molecular analysis of glycosaminoglycans in cutaneous lupus erythematosus and dermatomyositis. <i>Journal of Histochemistry and Cytochemistry</i> , <b>2011</b> , 59, 336-45	3.4	20
79	International consensus for a definition of disease flare in lupus. <i>Lupus</i> , <b>2011</b> , 20, 453-62	2.6	127
78	Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: evolution of a dogma. <i>Journal of Investigative Dermatology</i> , <b>2011</b> , 131, 1968-70	4.3	23
77	Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. <i>Archives of Dermatology</i> , <b>2011</b> , 147, 1261-7		94
76	Ultraviolet irradiation induces the accumulation of chondroitin sulfate, but not other glycosaminoglycans, in human skin. <i>PLoS ONE</i> , <b>2011</b> , 6, e14830	3.7	26
75	Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. <i>British Journal of Dermatology</i> , <b>2010</b> , 162, 669-73	4	43
74	Evaluating quality of life in dermatomyositis. <i>Expert Review of Dermatology</i> , <b>2010</b> , 5, 605-609		1
73	Clinical outcome measures for cutaneous lupus erythematosus. <i>Lupus</i> , <b>2010</b> , 19, 1137-43	2.6	17
72	European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1269-74	2.4	245

71	Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations. <i>Archives of Dermatology</i> , <b>2010</b> , 146, 729-38		41
70	Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument. <i>Rheumatic Disease Clinics of North America</i> , <b>2010</b> , 36, 33-51, vii	2.4	22
69	Rheumatic manifestations of skin disease. <i>Current Opinion in Rheumatology</i> , <b>2010</b> , 22, 78-84	5.3	12
68	Mycophenolate mofetil for interstitial lung disease in dermatomyositis. <i>Arthritis Care and Research</i> , <b>2010</b> , 62, 1496-501	4.7	106
67	The risk of ultraviolet radiation exposure from indoor lamps in lupus erythematosus. <i>Autoimmunity Reviews</i> , <b>2009</b> , 8, 320-4	13.6	28
66	TNF-alpha production in the skin. <i>Archives of Dermatological Research</i> , <b>2009</b> , 301, 87-91	3.3	104
65	UVB and proinflammatory cytokines synergistically activate TNF-alpha production in keratinocytes through enhanced gene transcription. <i>Journal of Investigative Dermatology</i> , <b>2009</b> , 129, 994-1001	4.3	85
64	Reliability and convergent validity of two outcome instruments for pemphigus. <i>Journal of Investigative Dermatology</i> , <b>2009</b> , 129, 2404-10	4.3	149
63	Analysis of compact fluorescent lights for use by patients with photosensitive conditions. <i>Photochemistry and Photobiology</i> , <b>2009</b> , 85, 1004-10	3.6	31
62	Lenalidomide for the treatment of resistant discoid lupus erythematosus. <i>Archives of Dermatology</i> , <b>2009</b> , 145, 303-6		38
61	Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. <i>Archives of Dermatology</i> , <b>2009</b> , 145, 255-60		38
60	Interventions for pemphigus vulgaris and pemphigus foliaceus. <i>The Cochrane Library</i> , <b>2009</b> , CD006263	5.2	68
59	Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. <i>British Journal of Dermatology</i> , <b>2008</b> , 159, 887-94	4	70
58	Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 58, 1043-6	4.5	372
57	Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. <i>Archives of Dermatology</i> , <b>2008</b> , 144, 25-32		64
56	The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. <i>Archives of Dermatology</i> , <b>2008</b> , 144, 173-80		75
55	Dermatomyositis. <i>Current Directions in Autoimmunity</i> , <b>2008</b> , 10, 313-32		31
54	Quality of life and disease severity in a cutaneous lupus erythematosus pilot study. <i>Archives of Dermatology</i> , <b>2008</b> , 144, 1061-2		14

53	Development of outcome measures for autoimmune dermatoses. <i>Archives of Dermatological Research</i> , <b>2008</b> , 300, 3-9	3.3	17
52	The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 59, 338-44		47
51	The cutaneous lupus disease activity and severity index as a validated outcome measure for cutaneous lupus erythematosus: comment on the article by Stamm et al. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 59, 601-2		5
50	Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus. <i>Dermatologic Therapy</i> , <b>2007</b> , 20, 93-101	2.2	44
49	Dermatologic therapeutics: thalidomide. A practical guide. <i>Dermatologic Therapy</i> , <b>2007</b> , 20, 175-86	2.2	14
48	Pathophysiology of cutaneous lupus erythematosus. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2007</b> , 33, 85-106	12.3	75
47	Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center. <i>Journal of the American Academy of Dermatology</i> , <b>2007</b> , 57, 937-43	4.5	39
46	Cutaneous lupus: insights into pathogenesis and disease classification. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , <b>2007</b> , 65, 200-4		36
45	Therapy of cutaneous lupus erythematosus. <i>Expert Review of Dermatology</i> , <b>2006</b> , 1, 105-120		2
44	Management of cutaneous dermatomyositis: current therapeutic options. <i>American Journal of Clinical Dermatology</i> , <b>2006</b> , 7, 341-51	7.1	36
43	Osteoporosis in health and disease: a dermatologist's perspective. <i>Dermatologic Clinics</i> , <b>2006</b> , 24, 241-9, vii	4.2	3
42	Failure of physiologic doses of pure UVA or UVB to induce lesions in photosensitive cutaneous lupus erythematosus: implications for phototesting. <i>Photodermatology Photoimmunology and Photomedicine</i> , <b>2006</b> , 22, 290-6	2.4	6
41	Medical dermatology: a view to the future. <i>Journal of Investigative Dermatology</i> , <b>2006</b> , 126, 528-9	4.3	2
40	Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. <i>Archives of Dermatology</i> , <b>2005</b> , 141, 699-702		28
39	Ultraviolet-B recruits mannose-binding lectin into skin from non-cutaneous sources. <i>Journal of Investigative Dermatology</i> , <b>2005</b> , 125, 166-73	4.3	14
38	The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. <i>Journal of Investigative Dermatology</i> , <b>2005</b> , 125, 889-94	4.3	280
37	Clinical manifestations of cutaneous lupus erythematosus. <i>Autoimmunity Reviews</i> , <b>2005</b> , 4, 296-302	13.6	95
36	Pathogenesis of Cutaneous Lupus Erythematosus: The Role of Ultraviolet Light <b>2005</b> , 251-266		2



35	Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. <i>Archives of Dermatology</i> , <b>2005</b> , 141, 855-9		61
34	Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus. <i>Lupus</i> , <b>2004</b> , 13, 839-49	2.6	78
33	Lupus erythematosus induced by medications, ultraviolet radiation, and other exogenous agents: a review, with special focus on the development of subacute cutaneous lupus erythematosus in a genetically predisposed individual. <i>International Journal of Dermatology</i> , <b>2004</b> , 43, 87-94	1.7	27
32	Photosensitivity in rheumatic diseases. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , <b>2004</b> , 9, 57-63	1.1	25
31	Tumid lupus erythematosus: criteria for classification with immunohistochemical analysis. <i>Arthritis and Rheumatism</i> , <b>2003</b> , 49, 494-500		61
30	IL-12 completely blocks ultraviolet-induced secretion of tumor necrosis factor alpha from cultured skin fibroblasts and keratinocytes. <i>Journal of Investigative Dermatology</i> , <b>2003</b> , 120, 116-22	4.3	24
29	Cutaneous infections of the head and neck. <i>Facial Plastic Surgery Clinics of North America</i> , <b>2003</b> , 11, 165-73		34
28	Multicentric reticulohistiocytosis presenting with clinical features of dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , <b>2003</b> , 48, S11-4	4.5	45
27	Thalidomide in cutaneous lupus erythematosus. <i>American Journal of Clinical Dermatology</i> , <b>2003</b> , 4, 379-87	1.1	22
26	Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. <i>Archives of Dermatology</i> , <b>2003</b> , 139, 991-3		34
25	Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. <i>Journal of Investigative Dermatology</i> , <b>2002</b> , 119, 617-20	4.3	64
24	Mannose binding lectin (MBL) polymorphisms associated with low MBL production in patients with dermatomyositis. <i>Journal of Investigative Dermatology</i> , <b>2002</b> , 119, 1394-9	4.3	43
23	Glucocorticoids in the treatment of bullous diseases. <i>Dermatologic Therapy</i> , <b>2002</b> , 15, 298-310	2.2	12
22	Ulcerating skin lesions and arthritis after a crab bite. <i>Journal of Clinical Rheumatology</i> , <b>2002</b> , 8, 181	1.1	
21	Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. <i>American Journal of Pathology</i> , <b>2002</b> , 161, 1077-86	5.8	88
20	Cutaneous lupus erythematosus: a review. <i>Dermatologic Clinics</i> , <b>2002</b> , 20, 373-85, v	4.2	105
19	Glucocorticoids in autoimmune connective tissue diseases. <i>Dermatologic Therapy</i> , <b>2001</b> , 14, 134-142	2.2	2
18	Preserving medical dermatology. A colleague lost, a call to arms, and a plan for battle. <i>Dermatologic Clinics</i> , <b>2001</b> , 19, 583-92	4.2	10

17	Dermatology vignette. Pseudoporphyria caused by NSAIDs. <i>Journal of Clinical Rheumatology</i> , <b>2001</b> , 7, 123	1.1	1
16	Association of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. <i>Journal of Investigative Dermatology</i> , <b>2000</b> , 115, 726-30	4.3	101
15	Wavelength-specific synergy between ultraviolet radiation and interleukin-1 alpha in the regulation of matrix-related genes: mechanistic role for tumor necrosis factor-alpha. <i>Journal of Investigative Dermatology</i> , <b>1999</b> , 113, 196-201	4.3	21
14	Lack of correlation of skin thickness with bone density in patients receiving chronic glucocorticoid. <i>Archives of Dermatological Research</i> , <b>1998</b> , 290, 388-93	3.3	9
13	Whither the patient-oriented researcher?. <i>Journal of the American Academy of Dermatology</i> , <b>1998</b> , 39, 109-13	4.5	5
12	The proper future for medical dermatology. <i>Archives of Dermatology</i> , <b>1998</b> , 134, 1159-60, 1161-2		5
11	Pathogenetic mechanisms and treatment of cutaneous lupus erythematosus. <i>Current Opinion in Rheumatology</i> , <b>1997</b> , 9, 400-9	5.3	18
10	UVB irradiation alters cellular responses to cytokines: role in extracellular matrix gene expression. <i>Journal of Investigative Dermatology</i> , <b>1997</b> , 108, 290-4	4.3	26
9	Elastic fiber-associated proteins of skin in development and photoaging. <i>Photochemistry and Photobiology</i> , <b>1996</b> , 63, 308-13	3.6	29
8	Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. <i>Archives of Dermatology</i> , <b>1996</b> , 132, 1435-9		9
7	Incidence of alopecia areata in lupus erythematosus. <i>Archives of Dermatology</i> , <b>1992</b> , 128, 368-71		13
6	Incidence of alopecia areata in lupus erythematosus. <i>Archives of Dermatology</i> , <b>1992</b> , 128, 368-371		59
5	Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. <i>Journal of the American Academy of Dermatology</i> , <b>1988</b> , 19, 961-5	4.5	51
4	Treatment of Discoid Skin Lesions With Azathioprine. <i>Archives of Dermatology</i> , <b>1986</b> , 122, 746		9
3	Nuclear lamin B is crucial to the nuclear envelope integrity and extracellular trap release in neutrophils		2
2	The early local and systemic Type I interferon responses to ultraviolet B light exposure are cGAS dependent		1
1	Cutaneous Diseases and the Esophagus763-781		1